FERRLECIT Drug Patent Profile
✉ Email this page to a colleague
When do Ferrlecit patents expire, and when can generic versions of Ferrlecit launch?
Ferrlecit is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in FERRLECIT is ferric oxyhydroxide. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ferric oxyhydroxide profile page.
Summary for FERRLECIT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 13 |
| Drug Prices: | Drug price information for FERRLECIT |
| What excipients (inactive ingredients) are in FERRLECIT? | FERRLECIT excipients list |
| DailyMed Link: | FERRLECIT at DailyMed |
Recent Clinical Trials for FERRLECIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| IRCCS Policlinico S. Matteo | Phase 3 |
| Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) | Phase 3 |
| Italian Group for Inflammatory Bowel Diseases (IG-IBD) | Phase 3 |
Pharmacology for FERRLECIT
| Drug Class | Parenteral Iron Replacement Phosphate Binder |
| Mechanism of Action | Phosphate Chelating Activity |
US Patents and Regulatory Information for FERRLECIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | FERRLECIT | ferric oxyhydroxide | INJECTABLE;INJECTION | 020955-001 | Feb 18, 1999 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
